Prospective Grant of Exclusive License: Calanolide Antiviral Compounds, Compositions, and Uses Thereof

Özet

This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the invention embodied in U.S. Patent Applications SN 07/861,249 and 08/065,618 both entitled ``Calanolide Antiviral Compounds, Compositions and Uses Thereof'' and related foreign patent applications to MediChem Research, Inc. of Lemont, IL. The patent rights in this invention have been assigned to the United States of America. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. It is anticipated that this license may be limited to the field of treatment of AIDS. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. The patent applications describe the chemical structures of and methods for isolating and purifying coumarins from an ext